Novo Nordisk A/S (NYSE:NVO) Trading Up 5.9% - Still a Buy?

Key Points

• Shares jumped 5.9% to about $40.79 after a late‑stage pediatric trial for oral semaglutide met its main goals, raising the prospect of a pediatric approval and expanded commercial sales.
• Analysts are mixed: the consensus rating is a Hold with an average target of ~$65.56, amid several price‑target cuts and neutral calls but including upgrades and a $175 target from Sanford Bernstein.
• Fundamentals remain solid—Novo Nordisk beat quarterly EPS estimates ($1.01 vs. $0.90) on $12.43B revenue, has a market cap near $182B and a PE of ~11.8, and recently paid a $1.2751 dividend.

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) rose 5.9% during trading on Friday . The company traded as high as $40.54 and last traded at $40.7870. Approximately 4,735,374 shares traded hands during trading, a decline of 79% from the average daily volume of 22,118,637 shares. The stock had previously closed at $38.52.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial met its main goals, positioning oral semaglutide to become the first oral GLP‑1 therapy for children with type‑2 diabetes — a clear commercial upside if approved. Novo Nordisk's new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Company statement and trial details highlight potential U.S. regulatory filing and commercial rollout for kids, which investors interpret as meaningful growth runway. Novo Nordisk's oral semaglutide demonstrates potential in children
• Positive Sentiment: News outlets report the trial win and frame it as a driver for near‑term stock strength and longer‑term sales growth from an expanded pediatric indication. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Neutral Sentiment: Coverage assesses whether current valuation already prices in recent setbacks and growth expectations — useful context but not immediate catalysts. Is Novo Nordisk Pricing Reflect Its Recent Share Slump And Growth Outlook
• Neutral Sentiment: Market reports note a recent pullback (day‑over‑day dip reported), providing technical context that can amplify volatility around drug‑news. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Citi recently cut its price target for NVO (to DKK 275) while keeping a neutral rating, signaling some analyst caution about near‑term upside despite the trial news. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Opinion pieces question whether the peak GLP‑1 growth era is past its best days, a thematic risk that could cap long‑term multiple expansion even if individual trial wins boost near‑term revenue. Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Morgan Stanley raised Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Zacks Research upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Finally, Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Price Performance

The firm has a 50-day moving average of $39.30 and a 200-day moving average of $47.94. The stock has a market cap of $182.06 billion, a PE ratio of 11.75, a PEG ratio of 9.32 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.34 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a $1.2751 dividend. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S's payout ratio is 50.43%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. XXEC Inc. boosted its holdings in shares of Novo Nordisk A/S by 487.1% during the 1st quarter. XXEC Inc. now owns 545,020 shares of the company's stock valued at $20,029,000 after purchasing an additional 452,185 shares during the last quarter. First Pacific Financial increased its holdings in shares of Novo Nordisk A/S by 4.9% in the first quarter. First Pacific Financial now owns 10,290 shares of the company's stock worth $378,000 after purchasing an additional 484 shares during the last quarter. Exeter Financial LLC lifted its position in shares of Novo Nordisk A/S by 197.8% in the first quarter. Exeter Financial LLC now owns 14,577 shares of the company's stock worth $536,000 after buying an additional 9,682 shares in the last quarter. Harbor Investment Advisory LLC grew its holdings in Novo Nordisk A/S by 10.9% during the 1st quarter. Harbor Investment Advisory LLC now owns 8,493 shares of the company's stock valued at $312,000 after buying an additional 837 shares in the last quarter. Finally, Brown Miller Wealth Management LLC bought a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $534,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.